Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Epilepsy ll: Types01:22

Epilepsy ll: Types

Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multiscale in vivo imaging of tumor evolution using a germline conditional triple-reporter mouse.

Nature biotechnology·2026
Same author

Epilepsy surgery in pediatric patients with complex COL4A1/2-associated epilepsy.

Epileptic disorders : international epilepsy journal with videotape·2026
Same author

Association of behavioral problems and health-related quality of life in children with epilepsy.

Epilepsy & behavior : E&B·2026
Same author

Thalamic oscillations distinguish natural states of consciousness in humans.

Nature human behaviour·2026
Same author

Termination of super-refractory status epilepticus following stereo-EEG implantation.

Epileptic disorders : international epilepsy journal with videotape·2026
Same author

Determinants of accuracy in frame-based stereoelectroencephalography: the role of experience, workflow, and selective use of guiding devices.

Frontiers in neurology·2026

Related Experiment Video

Updated: May 10, 2026

Network Analysis of Foramen Ovale Electrode Recordings in Drug-resistant Temporal Lobe Epilepsy Patients
09:32

Network Analysis of Foramen Ovale Electrode Recordings in Drug-resistant Temporal Lobe Epilepsy Patients

Published on: December 18, 2016

P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study.

Maria Feldmann1, Marie-Claude Asselin, Joan Liu

  • 1Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, London, UK.

The Lancet. Neurology
|June 22, 2013
PubMed
Summary

In temporal lobe epilepsy, higher P-glycoprotein activity in the brain is linked to drug resistance. Targeting P-glycoprotein may offer a new treatment strategy for epilepsy pharmacoresistance.

More Related Videos

Preparation and Implantation of Electrodes for Electrically Kindling VGAT-Cre Mice to Generate a Model for Temporal Lobe Epilepsy
09:29

Preparation and Implantation of Electrodes for Electrically Kindling VGAT-Cre Mice to Generate a Model for Temporal Lobe Epilepsy

Published on: August 17, 2021

Using a Bipolar Electrode to Create a Temporal Lobe Epilepsy Mouse Model by Electrical Kindling of the Amygdala
09:49

Using a Bipolar Electrode to Create a Temporal Lobe Epilepsy Mouse Model by Electrical Kindling of the Amygdala

Published on: June 29, 2022

Related Experiment Videos

Last Updated: May 10, 2026

Network Analysis of Foramen Ovale Electrode Recordings in Drug-resistant Temporal Lobe Epilepsy Patients
09:32

Network Analysis of Foramen Ovale Electrode Recordings in Drug-resistant Temporal Lobe Epilepsy Patients

Published on: December 18, 2016

Preparation and Implantation of Electrodes for Electrically Kindling VGAT-Cre Mice to Generate a Model for Temporal Lobe Epilepsy
09:29

Preparation and Implantation of Electrodes for Electrically Kindling VGAT-Cre Mice to Generate a Model for Temporal Lobe Epilepsy

Published on: August 17, 2021

Using a Bipolar Electrode to Create a Temporal Lobe Epilepsy Mouse Model by Electrical Kindling of the Amygdala
09:49

Using a Bipolar Electrode to Create a Temporal Lobe Epilepsy Mouse Model by Electrical Kindling of the Amygdala

Published on: June 29, 2022

Area of Science:

  • Neuroscience
  • Pharmacology
  • Epilepsy Research

Background:

  • P-glycoprotein, a transporter at the blood-brain barrier, is implicated in antiepileptic drug resistance.
  • Rodent models suggest P-glycoprotein reduces drug concentrations at the target site.
  • This study investigates P-glycoprotein activity in human temporal lobe epilepsy patients.

Purpose of the Study:

  • To assess in vivo P-glycoprotein activity in patients with temporal lobe epilepsy.
  • To determine if P-glycoprotein activity differs between pharmacoresistant and seizure-free epilepsy patients.
  • To explore the relationship between P-glycoprotein activity and seizure frequency.

Main Methods:

  • Positron Emission Tomography (PET) with (R)-[(11)C]verapamil was used to measure P-glycoprotein substrate transport.
  • Voxel-by-voxel analysis calculated the plasma-to-brain transport rate constant (K1).
  • P-glycoprotein activity was assessed at baseline and after administration of the inhibitor tariquidar.

Main Results:

  • Pharmacoresistant patients exhibited lower baseline K1, indicating higher P-glycoprotein activity, in specific brain regions compared to seizure-free patients.
  • Higher P-glycoprotein activity correlated with increased seizure frequency.
  • Healthy controls showed a significantly greater increase in K1 after tariquidar administration than pharmacoresistant patients, particularly in the hippocampus.

Conclusions:

  • Results support an association between P-glycoprotein overactivity and pharmacoresistance in temporal lobe epilepsy.
  • P-glycoprotein may contribute to drug resistance in epilepsy.
  • Inhibiting P-glycoprotein could be a potential therapeutic strategy for epilepsy treatment.